Evidence of the sensitivity of the MoCA alternate forms in monitoring cognitive change in early alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 37, Issue 1-2, 2014, Pages 95-103

  Costa, Ana Sofia ^a   Reich, Arno ^a   Fimm, Bruno ^a   Ketteler, Simon Thomas ^a   Schulz, Joerg Bernhard ^a,c   Reetz, Kathrin ^a,b,c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c Julich Aachen Research Alliance JARA   (Germany)

Author keywords

Alzheimer's disease; Change; Montreal Cognitive Assessment; Screening instrument

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL DEMENTIA RATING; COHORT ANALYSIS; CONSORTIUM TO ESTABLISH A REGISTRY OF ALZHEIMER DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MALE; MENTAL DETERIORATION; MONTREAL COGNITIVE ASSESSMENT TEST; NEUROPSYCHOLOGICAL TEST; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; SENSITIVITY ANALYSIS; ATTENTION; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COMPARATIVE STUDY; CONSORTIUM TO ESTABLISH A REGISTRY OF ALZHEIMER DISEASE PLUS BATTERY; CONTROLLED STUDY; DEPTH PERCEPTION; DIAGNOSTIC TEST ACCURACY STUDY; EFFECT SIZE; EXECUTIVE FUNCTION; GERIATRIC DEPRESSION SCALE; LANGUAGE; MEMORY; MONTREAL COGNITIVE ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORIENTATION; REGISTER; SENSITIVITY AND SPECIFICITY; WHITE MATTER LESION;

AMYLOID BETA PROTEIN[1-42];

AGE OF ONSET; AGED; ALZHEIMER DISEASE; AMYLOIDOGENIC PROTEINS; ATROPHY; BIOLOGICAL MARKERS; BRAIN; COGNITION; COGNITION DISORDERS; DATA INTERPRETATION, STATISTICAL; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TAU PROTEINS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84896718626     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000351864     Document Type: Article

References (37)

1. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53: 695-699.
2. Koski L, Xie H, Finch L: Measuring cognition in a geriatric outpatient clinic: Rasch analysis of the Montreal Cognitive Assessment. J Geriatr Psychiatry Neurol 2009; 22: 151-160.
3. Dong Y, Venketasubramanian N, Chan BP, Sharma VK, Slavin MJ, Collinson SL, Sachdev P, Chan YH, Chen CL: Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3-6 months after stroke. J Neurol Neurosurg Psychiatry 2012; 83: 580-585.
4. Popovic IM, Seric V, Demarin V: Mild cognitive impairment in symptomatic and asymptomatic cerebrovascular disease. J Neurol Sci 2007; 257: 185-193.
5. Lessig S, Nie D, Xu R, Corey-Bloom J: Changes on brief cognitive instruments over time in Parkinson's disease. Mov Disord 2012; 27: 1125-1128.
6. Heilbronner RL, Sweet JJ, Attix DK, Krull KR, Henry GK, Hart RP: Official position of the American Academy of Clinical Neuropsychology on serial neuropsychological assessments: the utility and challenges of repeat test administrations in clinical and forensic contexts. Clin Neuropsychol 2010; 24: 1267-1278.
7. Costa AS, Fimm B, Friesen P, Soundjock H, Rottschy C, Gross T, Eitner F, Reich A, Schulz JB, Nasreddine ZS, Reetz K: Alternate-form reliability of the Montreal Cognitive Assessment screening test in a clinical setting. Dement Geriatr Cogn Disord 2012; 33: 379-384.
8. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P: Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-1127.
9. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G: Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-746.
10. Gauthier S, Dubois B, Feldman H, Scheltens P: Revised research diagnostic criteria for Alzheimer's disease. Lancet Neurol 2008; 7: 668-670.
11. Reiber H: Liquordiagnostik: Labor und Diagnose. Frankfurt, TH Books, 2005.
12. Zettl UK, Lehmitz R, Mix E: Klinische Liquordiagnostik. Berlin, de Gruyter, 2005.
13. Pasquier F, Leys D, Weerts JG, Mounier-Vehier F, Barkhof F, Scheltens P: Inter-and intraobserver reproducibility of cerebral atrophy assessment on MRI scans with hemispheric infarcts. Eur Neurol 1996; 36: 268-272.
14. Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, Kuiper M, Steinling M, Wolters EC, Valk J: Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992; 55: 967-972.
15. Koedam EL, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YA, Fox N, Barkhof F, Wattjes MP: Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011; 21: 2618-2625.
16. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA: MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. Am J Neuroradiol 1987; 8: 421-426.
17. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 9(suppl 1):173-176, discussion 177-178.
18. Aebi C: Validierung der Neuropsychologischen Testbatterie CERAD-NP: Eine Multi-Center Studie; PhD thesis, University of Basel, Basel, 2002.
19. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey MB, Leirer VO: Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1983; 37-49.
20. Gauggel S, Birkner B: Validation and reliability of a German version of the geriatric depression scale (in German). Z Klin Psychol 1999; 18-27.
21. Duro D, Simoes MR, Ponciano E, Santana I: Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. J Neurol 2010; 257: 728-734.
22. Chandler MJ, Lacritz LH, Hynan LS, Barnard HD, Allen G, Deschner M, Weiner MF, Cullum CM: A total score for the CERAD neuropsychological battery. Neurology 2005; 65: 102-106.
23. O'Bryant SE, Lacritz LH, Hall J, Waring SC, Chan W, Khodr ZG, Massman PJ, Hobson V, Cullum CM: Validation of the new interpretive guidelines for the Clinical Dementia Rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol 2010; 67: 746-749.
24. Husted JA, Cook RJ, Farewell VT, Gladman DD: Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000; 53: 459-468.
25. Middel B, van Sonderen E: Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of interventionrelated change in health services research. Int J Integr Care 2002; 2:e15.
26. Middel B, van Sonderen E: Responsiveness and validity of 3 outcome measures of motor function after stroke rehabilitation. Stroke 2010; 41:e463-e464, author reply e465.
27. Cohen J: Statistical Power Analysis for the Behavioural Sciences. Hilsdale, Lawrence Eribaum Associates, 1988.
28. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ: The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-1725.
29. Kasten M, Bruggemann N, Schmidt A, Klein C: Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2010; 75: 478, author reply 478-479.
30. Blair M, Marczinski CA, Davis-Faroque N, Kertesz A: A longitudinal study of language decline in Alzheimer's disease and frontotemporal dementia. J Int Neuropsychol Soc 2007; 13: 237-245.
31. Paxton JL, Peavy GM, Jenkins C, Rice VA, Heindel WC, Salmon DP: Deterioration of visual-perceptual organization ability in Alzheimer's disease. Cortex 2007; 43: 967-975.
32. Rossetti HC, Lacritz LH, Cullum CM, Weiner MF: Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample. Neurology 2011; 77: 1272-1275.
33. Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, et al: Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. PLoS One 2012; 7:e38639.
34. Tschanz JT, Corcoran CD, Schwartz S, Treiber K, Green RC, Norton MC, Mielke MM, Piercy K, Steinberg M, Rabins PV, Leoutsakos JM, Welsh-Bohmer KA, Breitner JC, Lyketsos CG: Progression of cognitive, functional, and neuropsychiatric symptom domains in a population cohort with Alzheimer dementia: the CACHE County Dementia Progression study. Am J Geriatr Psychiatry 2011; 19: 532-542.
35. Paajanen T, Hanninen T, Tunnard C, Mecocci P, Sobow T, Tsolaki M, Vellas B, Lovestone S, Soininen H, Add Neuro Med Consortium: CERAD neuropsychological battery total score in multinational mild cognitive impairment and control populations: the Add Neuro Med study. J Alzheimers Dis 2010; 22: 1089-1097.
36. Freitas S, Simoes MR, Alves L, Santana I: Montreal Cognitive Assessment: influence of sociodemographic and health variables. Arch Clin Neuropsychol 2012; 27: 165-175.
37. Smits LL, Pijnenburg YA, Koedam EL, van der Vlies AE, Reuling IE, Koene T, Teunissen CE, Scheltens P, van der Flier WM: Early onset Alzheimer's disease is associated with a distinct neuropsychological profile. J Alzheimers Dis 2012; 30: 101-108.